Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $109.62M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 0.86M
Average 0.66M
Returns on capital
Upstream Bio, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-42.2%
avg -4.1%
ROIC
-47.0%
avg -68.5%
ROA
-40.5%
avg -50.1%
Analysis
ROA is currently the strongest return metric at -40.5% versus its period average of -50.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
E. Rand Sutherland | Chief Executive Officer & Director | USD 1M | 56 | — | — |
Aaron Deykin | Chief Medical Officer and Head of Research & Development | USD 741.8K | 59 | 32.30K | 0.06% |
Michael Paul Gray | Chief Financial Officer & Chief Operating Officer | USD 706.3K | 55 | — | — |
Allison Ambrose | Senior Vice President, General Counsel & Secretary | USD 59.79K | 41 | 15.56K | 0.03% |
Fang Xie | Vice President & Head of Biometrics | — | — | — | — |
Lisa Fiering | Senior Vice President of People & Culture | — | — | — | — |
Mersedeh Miraliakbari | Senior Vice President of Regulatory Affairs & Quality | — | — | — | — |
Stacy Price | Chief Technology Officer | — | 57 | — | — |
Adam Houghton | Chief Business Officer | — | 55 | 22.90K | 0.04% |
Meggan Buckwell | Director of Corporate Communications & Investor Relations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 16, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
15
$104,796.49
Net Transaction Value
−$104,796.49
Net selling
Most Active
GRAY MICHAEL
3 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 16, 26Sep 16, 2026 | GRAY MICHAEL Direct | Sell | $4.7K$4,682.97 |
| Sep 16, 26Sep 16, 2026 | Ambrose Allison Direct | Sell | $2.7K$2,662.65 |
| Sep 16, 26Sep 16, 2026 | Deykin Aaron Direct | Sell | $4.9K$4,913.55 |
| Sep 16, 26Sep 16, 2026 | Sutherland Everett Rand Direct | Sell | $11.5K$11,501.55 |
| Sep 16, 26Sep 16, 2026 | Houghton Adam Direct | Sell | $3.8K$3,843.00 |
| Jun 16, 26Jun 16, 2026 | GRAY MICHAEL Direct | Sell | $5.2K$5,203.30 |
| Jun 16, 26Jun 16, 2026 | Sutherland Everett Rand Direct | Sell | $12.8K$12,779.50 |
| Jun 16, 26Jun 16, 2026 | Houghton Adam Direct | Sell | $4.3K$4,270.00 |
| Jun 16, 26Jun 16, 2026 | Deykin Aaron Direct | Sell | $5.5K$5,459.50 |
| Jun 16, 26Jun 16, 2026 | Ambrose Allison Direct | Sell | $2.9K$2,909.70 |
1–10 of 15
Summary
Insiders reported 0 buys worth $0.00 and 15 sells worth $104,796.49 over the last 12 months. That adds up to net selling of $104,796.49. GRAY MICHAEL was the most active insider with 3 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +33.0% | +76.3% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +33.0% over three years. Forward estimates point to Revenue at +76.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does Upstream Bio, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about UPB's management, answered from reported figures.
Who manages UPB?
Upstream Bio, Inc. (UPB) lists 10 active executives. The top listed executive is Fang Xie, Vice President & Head of Biometrics.
Are UPB insiders buying or selling?
Recent insider activity shows net buying of $77.06M.
Continue the stock analysis
Jump to another research area for this company.